Quarterly report pursuant to Section 13 or 15(d)

Deferred Revenue

v3.3.0.814
Deferred Revenue
9 Months Ended
Sep. 30, 2015
Deferred Revenue Disclosure [Abstract]  
Deferred Revenue

7.

DEFERRED REVENUE

In May 2015, the Company received $1,250,000 after signing the CFFT award agreement (See Note 3 and Note 12).  The Company recorded the $1,250,000 as deferred revenue. The Company is amortizing the deferred revenue and recognizing revenue on a straight-line basis over the performance period for the development program which is expected to conclude during the first quarter of 2017. For the three and nine months ended September 30, 2015 the Company recorded revenue of $170,454 and $284,090, respectively. In October 2015, the Company billed the CFFT an additional $1,250,000 that was due upon the milestone achievement of dosing of the first patient (See Note 14). Deferred revenue consists of the following:

 

 

 

September 30,

 

 

December 31,

 

 

 

2015

 

 

2014

 

Deferred revenue

 

 

965,910

 

 

$

 

Less: current portion

 

 

681,816

 

 

 

 

Long-term portion

 

$

284,094

 

 

$